GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2007

Biovail Gains License to Two Pharma Pass II Early-Stage Compounds

  • Biovail acquired the worldwide rights to two reportedly early-stage candidates from Pharma Pass II (PPII). BVF-068 is being investigated for the treatment of a central nervous system (CNS) disorder, and BVF-247 is a novel formulation of a cardiovascular agent, according to the companies.

    Biovail will develop, manufacture, and market both compounds. PPII will receive an upfront fee, milestone payments for each product, and tiered, single-digit royalties on net commercial sales.

    “These two products target large global markets and have the potential to address safety issues inherent in the currently marketed formulations,” points out Douglas Squires, Ph.D., Biovail's CEO.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »